Table 5.
Hepatitis B virus antigen/antibody and hepatitis C virus antibody
|
Hepatocellular carcinoma n (%) |
Intrahepatic cholangiocarcinoma n (%) |
Combined hepatocellular cholangiocarcinoma n (%) |
|
|---|---|---|---|
| HBsAg | n = 18 219 | n = 934 | n = 147 |
| Negative | 15 449 (84.8) | 857 (91.8) | 123 (83.7) |
| Positive | 2768 (15.2) | 77 (8.2) | 24 (16.3) |
| Equivocal | 2 (0.0) | 0 (0.0) | 0 (0.0) |
| HBsAb | n = 5670 | n = 251 | n = 45 |
| Negative | 4362 (76.9) | 190 (75.7) | 34 (75.6) |
| Positive | 1267 (22.3) | 61 (24.3) | 10 (22.2) |
| Equivocal | 41 (0.7) | 0 (0.0) | 1 (2.2) |
| HBcAb | n = 6033 | n = 229 | n = 62 |
| Negative | 2850 (47.2) | 129 (56.3) | 33 (53.2) |
| Positive | 3141 (52.1) | 100 (43.7) | 29 (46.8) |
| Equivocal | 42 (0.7) | 0 (0.0) | 0 (0.0) |
| HBeAg | n = 4030 | n = 152 | n = 42 |
| Negative | 3456 (85.8) | 141 (92.8) | 39 (92.9) |
| Positive | 569 (14.1) | 11 (7.2) | 3 (7.1) |
| Equivocal | 5 (0.1) | 0 (0.0) | 0 (0.0) |
| HBeAb | n = 4006 | n = 151 | n = 46 |
| Negative | 2155 (53.8) | 90 (59.6) | 22 (47.8) |
| Positive | 1837 (45.9) | 61 (40.4) | 24 (52.2) |
| Equivocal | 14 (0.3) | 0 (0.0) | 0 (0.0) |
| HBV‐DNA load | n = 1379 | n = 20 | n = 9 |
| <3.7 LGE | 65 (4.7) | 0 (0.0) | 0 (0.0) |
| 3.7–3.9 LGE | 24 (1.7) | 0 (0.0) | 0 (0.0 |
| 4.0–4.9 LGE | 39 (2.8) | 0 (0.0) | 0 (0.0) |
| 5.0–5.9 LGE | 27 (2.0) | 0 (0.0) | 0 (0.0) |
| 6.0–6.9 LGE | 34 (2.5) | 0 (0.0) | 0 (0.0) |
| 7.0–7.9 LGE | 25 (1.8) | 0 (0.0) | 0 (0.0) |
| 8.0–8.7 LGE | 9 (0.7) | 0 (0.0) | 0 (0.0) |
| >8.7 LGE | 2 (0.1) | 0 (0.0) | 0 (0.0) |
| <2.1 Logcopy | 90 (6.5) | 2 (10.0) | 0 (0.0) |
| 2.1–2.9 Logcopy | 269 (19.5) | 7 (35.0) | 1 (11.1) |
| 3.0–3.9 Logcopy | 176 (12.8) | 3 (15.0) | 3 (33.3) |
| 4.0–4.9 Logcopy | 145 (10.5) | 1 (5.0) | 0 (0.0) |
| 5.0–5.9 Logcopy | 131 (9.5) | 2 (10.0) | 1 (11.1) |
| 6.0–6.9 Logcopy | 201 (14.6) | 3 (15.0) | 3 (33.3 |
| 7.0–7.9 Logcopy | 114 (8.3) | 2 (10.0) | 1 (11.1) |
| 8.0–8.8 Logcopy | 26 (1.9) | 0 (0.0) | 0 (0.0) |
| >8.8 Logcopy | 2 (0.1) | 0 (0.0) | 0 (0.0) |
| HCV‐Ab | n = 18 097 | n = 931 | n = 13 |
| Negative | 7094 (39.2) | 790 (84.9) | 86 (64.7) |
| Positive | 10 976 (60.7) | 139 (14.9) | 47 (35.3) |
| Equivocal | 27 (0.1) | 2 (0.2) | 0 (0.0) |
| HCV‐RNA | n = 3761 | n = 69 | n = 22 |
| Negative | 885 (23.5) | 38 (55.1) | 10 (45.5) |
| <1.2 | 41 (1.1) | 1 (1.4) | 0 (0.0) |
| 1.2–2.9 | 98 (2.6) | 1 (1.4) | 2 (9.1) |
| 3.0–4.9 | 428 (11.4) | 5 (7.2) | 2 (9.1) |
| 5.0–6.9 | 2006 (53.3) | 18 (26.1) | 6 (27.3) |
| 7.0– logIU/mL | 303 (8.1) | 6 (8.7) | 2 (9.1) |
For all parameters, n is the total number of patients, excluding those in the “unknown” category, and (%) is the percentage of n.
HBcAb, antibody to hepatitis B core antigen; HBeAb, antibody to hepatitis B e antigen; HBeAg, hepatitis B e antigen; HBsAb, antibody to hepatitis B surface antigen; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; HCV, hepatitis C virus.